Green Eric Mark

SEC source: 0001127602-24-014765 · form4.xml · nonDerivative · entry 1

Green Eric Mark · CIK 0001336007 · Director · President, CEO and Board Chair

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 162,224.1245

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The shares reported were acquired by the Reporting Person from exercising a portion of a stock option award expiring in either 2025 or 2026, pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was completed pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on 11/17/2023.

SEC source: 0001127602-24-021890 · form4a.xml · derivative · entry 11

Green Eric Mark · CIK 0001336007 · Director · President, CEO and Board Chair

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 36,732

Underlying: Common Stock · 9,000 shares

Expires 2026-02-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-24-021890 · form4a.xml · derivative · entry 10

Green Eric Mark · CIK 0001336007 · Director · President, CEO and Board Chair

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 45,732

Underlying: Common Stock · 41,000 shares

Expires 2026-02-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-24-021890 · form4a.xml · derivative · entry 9

Green Eric Mark · CIK 0001336007 · Director · President, CEO and Board Chair

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,684 shares

Expires 2025-04-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-24-021890 · form4a.xml · derivative · entry 8

Green Eric Mark · CIK 0001336007 · Director · President, CEO and Board Chair

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,316 shares

Expires 2025-04-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-24-021890 · form4a.xml · nonDerivative · entry 7

Green Eric Mark · CIK 0001336007 · Director · President, CEO and Board Chair

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 161,908.1245

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The shares reported were acquired by the Reporting Person from exercising a portion of a stock option award expiring in either 2025 or 2026, pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was completed pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on 11/17/2023.

SEC source: 0001127602-24-021890 · form4a.xml · nonDerivative · entry 6

Green Eric Mark · CIK 0001336007 · Director · President, CEO and Board Chair

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 152,908.1245

F1 · security: The shares reported were acquired by the Reporting Person from exercising a portion of a stock option award expiring in either 2025 or 2026, pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was completed pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on 11/17/2023.

F2 · price: The price reported in Column 4 is a weighted average price.

SEC source: 0001127602-24-021890 · form4a.xml · nonDerivative · entry 5

Green Eric Mark · CIK 0001336007 · Director · President, CEO and Board Chair

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 193,908.1245

F1 · security: The shares reported were acquired by the Reporting Person from exercising a portion of a stock option award expiring in either 2025 or 2026, pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was completed pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on 11/17/2023.

F2 · price: The price reported in Column 4 is a weighted average price.

SEC source: 0001127602-24-021890 · form4a.xml · nonDerivative · entry 4

Green Eric Mark · CIK 0001336007 · Director · President, CEO and Board Chair

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 209,952.1245

F1 · security: The shares reported were acquired by the Reporting Person from exercising a portion of a stock option award expiring in either 2025 or 2026, pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was completed pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on 11/17/2023.

F2 · price: The price reported in Column 4 is a weighted average price.

SEC source: 0001127602-24-021890 · form4a.xml · nonDerivative · entry 3

Green Eric Mark · CIK 0001336007 · Director · President, CEO and Board Chair

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 218,908.1245

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The shares reported were acquired by the Reporting Person from exercising a portion of a stock option award expiring in either 2025 or 2026, pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was completed pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on 11/17/2023.

SEC source: 0001127602-24-021890 · form4a.xml · nonDerivative · entry 2

Green Eric Mark · CIK 0001336007 · Director · President, CEO and Board Chair

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 177,908.1245

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The shares reported were acquired by the Reporting Person from exercising a portion of a stock option award expiring in either 2025 or 2026, pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was completed pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on 11/17/2023.

SEC source: 0001127602-24-021890 · form4a.xml · nonDerivative · entry 1

Green Eric Mark · CIK 0001336007 · Director · President, CEO and Board Chair

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 162,224.1245

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The shares reported were acquired by the Reporting Person from exercising a portion of a stock option award expiring in either 2025 or 2026, pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was completed pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on 11/17/2023.

SEC source: 0001415889-24-012609 · form4-05082024_080532.xml · derivative · entry 2

Green Eric Mark · CIK 0001336007 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 934

Underlying: Common Stock · 934 shares

Expires 2034-05-06

F1 · derivative.exercise_date: The option will become exercisable, on a cumulative basis, as to 25% of the option shares (excluding any fractional portion less than one share), on the last day of each of the first, second and third three-month periods following its date of grant and as to the remaining shares on the last day of the fourth three-month period following its date of grant; provided, however, that if a Change in Control of the Company (as that term is defined in the Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan) will occur, then the option will become immediately exercisable in full. The date listed in the Date Exercisable column represents the first vesting date.

SEC source: 0001415889-24-009799 · form4-04022024_080447.xml · nonDerivative · entry 2

Green Eric Mark · CIK 0001336007 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,714.39

F1 · balance_after: Includes 3.21 shares acquired pursuant to a dividend reinvestment feature of the Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan.

SEC source: 0001415889-24-009799 · form4-04022024_080447.xml · nonDerivative · entry 1

Green Eric Mark · CIK 0001336007 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,575.79

SEC source: 0001127602-24-007632 · form4.xml · derivative · entry 5

Green Eric Mark · CIK 0001336007 · Director · President, CEO and Board Chair

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,684

Underlying: Common Stock · 64,132 shares

Expires 2025-04-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-24-007632 · form4.xml · derivative · entry 4

Green Eric Mark · CIK 0001336007 · Director · President, CEO and Board Chair

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,316

Underlying: Common Stock · 9,000 shares

Expires 2025-04-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-24-007632 · form4.xml · nonDerivative · entry 3

Green Eric Mark · CIK 0001336007 · Director · President, CEO and Board Chair

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 152,908.1245

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The shares reported were acquired by the Reporting Person from exercising a portion of a stock option award expiring in 2025, pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was completed pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on 11/17/2023.

SEC source: 0001127602-24-007632 · form4.xml · nonDerivative · entry 2

Green Eric Mark · CIK 0001336007 · Director · President, CEO and Board Chair

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 152,908.1245

F1 · security: The shares reported were acquired by the Reporting Person from exercising a portion of a stock option award expiring in 2025, pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was completed pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on 11/17/2023.

F2 · price: The price reported in Column 4 is a weighted average price.

SEC source: 0001127602-24-007632 · form4.xml · nonDerivative · entry 1

Green Eric Mark · CIK 0001336007 · Director · President, CEO and Board Chair

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 217,040.1245

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The shares reported were acquired by the Reporting Person from exercising a portion of a stock option award expiring in 2025, pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was completed pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on 11/17/2023.

SEC source: 0001127602-24-006385 · form4.xml · derivative · entry 2

Green Eric Mark · CIK 0001336007 · Director · President, CEO and Board Chair

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,221

Underlying: Stock Options (Right to Buy) · 25,221 shares

Expires 2034-02-20

F2 · derivative.exercise_date: This grant vests in four equal installments beginning on February 20, 2025.

SEC source: 0001127602-24-006385 · form4.xml · nonDerivative · entry 1

Green Eric Mark · CIK 0001336007 · Director · President, CEO and Board Chair

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 148,202.6695

F1 · security: 2021 PSUs (PP20) award vesting net of taxes withheld.

SEC source: 0001415889-24-000387 · form4-01032024_110135.xml · nonDerivative · entry 2

Green Eric Mark · CIK 0001336007 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,429.56

F1 · balance_after: Includes 2.42 shares acquired pursuant to a dividend reinvestment feature of the Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan.

SEC source: 0001415889-24-000387 · form4-01032024_110135.xml · nonDerivative · entry 1

Green Eric Mark · CIK 0001336007 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,276.11

SEC source: 0001127602-23-029124 · form4.xml · nonDerivative · entry 1

Green Eric Mark · CIK 0001336007 · Director · President, CEO and Board Chair

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 130,774.0865

F1 · kind: This transaction represents a charitable gift donation to a private, non-profit educational institution for which Mr. Green received no compensatory benefit

SEC source: 0001415889-23-013893 · form4-10032023_081016.xml · nonDerivative · entry 2

Green Eric Mark · CIK 0001336007 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,118.78

F1 · balance_after: Includes 1.21 shares acquired pursuant to a dividend reinvestment feature of the Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan.

SEC source: 0001415889-23-013893 · form4-10032023_081016.xml · nonDerivative · entry 1

Green Eric Mark · CIK 0001336007 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 941.13

SEC source: 0001562180-23-006265 · primarydocument.xml · derivative · entry 11

Green Eric Mark · CIK 0001336007 · Director · President & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 98,132

Underlying: Common Stock · 50,000 shares

Expires 2025-04-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F10 · derivative.exercise_date: This option is fully vested.

SEC source: 0001562180-23-006265 · primarydocument.xml · nonDerivative · entry 10

Green Eric Mark · CIK 0001336007 · Director · President & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 140,574.0865

F2 · shares: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 5/5/2023. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. In total, 50,000 options were exercised with 44,000 shares sold and 6,000 shares held by the reporting person.

SEC source: 0001562180-23-006265 · primarydocument.xml · nonDerivative · entry 9

Green Eric Mark · CIK 0001336007 · Director · President & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 140,674.0865

F2 · shares: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 5/5/2023. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. In total, 50,000 options were exercised with 44,000 shares sold and 6,000 shares held by the reporting person.

F9 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $397.73 to $398.17, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.

SEC source: 0001562180-23-006265 · primarydocument.xml · nonDerivative · entry 8

Green Eric Mark · CIK 0001336007 · Director · President & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 141,774.0865

F2 · shares: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 5/5/2023. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. In total, 50,000 options were exercised with 44,000 shares sold and 6,000 shares held by the reporting person.

F8 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $396.73 to $397.62, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.

SEC source: 0001562180-23-006265 · primarydocument.xml · nonDerivative · entry 7

Green Eric Mark · CIK 0001336007 · Director · President & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 149,306.0865

F2 · shares: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 5/5/2023. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. In total, 50,000 options were exercised with 44,000 shares sold and 6,000 shares held by the reporting person.

F7 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $395.73 to $396.67, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.

SEC source: 0001562180-23-006265 · primarydocument.xml · nonDerivative · entry 6

Green Eric Mark · CIK 0001336007 · Director · President & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 156,006.0865

F2 · shares: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 5/5/2023. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. In total, 50,000 options were exercised with 44,000 shares sold and 6,000 shares held by the reporting person.

F6 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $394.65 to $395.60, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.

SEC source: 0001562180-23-006265 · primarydocument.xml · nonDerivative · entry 5

Green Eric Mark · CIK 0001336007 · Director · President & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 163,690.0865

F2 · shares: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 5/5/2023. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. In total, 50,000 options were exercised with 44,000 shares sold and 6,000 shares held by the reporting person.

F5 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $393.64 to $394.63, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.

SEC source: 0001562180-23-006265 · primarydocument.xml · nonDerivative · entry 4

Green Eric Mark · CIK 0001336007 · Director · President & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 172,019.0865

F2 · shares: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 5/5/2023. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. In total, 50,000 options were exercised with 44,000 shares sold and 6,000 shares held by the reporting person.

F4 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $392.625 to $393.60, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.

SEC source: 0001562180-23-006265 · primarydocument.xml · nonDerivative · entry 3

Green Eric Mark · CIK 0001336007 · Director · President & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 179,074.0865

F2 · shares: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 5/5/2023. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. In total, 50,000 options were exercised with 44,000 shares sold and 6,000 shares held by the reporting person.

F3 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $391.59 to $392.57, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.

SEC source: 0001562180-23-006265 · primarydocument.xml · nonDerivative · entry 2

Green Eric Mark · CIK 0001336007 · Director · President & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 183,574.0865

F2 · shares: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 5/5/2023. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. In total, 50,000 options were exercised with 44,000 shares sold and 6,000 shares held by the reporting person.

SEC source: 0001562180-23-006265 · primarydocument.xml · nonDerivative · entry 1

Green Eric Mark · CIK 0001336007 · Director · President & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 184,574.0865

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The shares reported were acquired by the Reporting Person from exercising a portion of a stock option award expiring in 2025, pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was completed pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on 5/5/2023.

SEC source: 0001415889-23-010768 · form4-07052023_080756.xml · nonDerivative · entry 2

Green Eric Mark · CIK 0001336007 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 757.34

F1 · balance_after: Includes 0.18 shares acquired pursuant to a dividend reinvestment feature of the Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan.

SEC source: 0001415889-23-010768 · form4-07052023_080756.xml · nonDerivative · entry 1

Green Eric Mark · CIK 0001336007 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 595.76

SEC source: 0001562180-23-004067 · primarydocument.xml · derivative · entry 7

Green Eric Mark · CIK 0001336007 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 148,132

Underlying: Common Stock · 50,000 shares

Expires 2025-04-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: This option is fully vested.

SEC source: 0001562180-23-004067 · primarydocument.xml · nonDerivative · entry 6

Green Eric Mark · CIK 0001336007 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 134,574.0865

F2 · shares: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 9/14/2022. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. In total, 50,000 options were exercised with 44,000 shares sold and 6,000 shares held by the reporting person.

F7 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $365.43 to $365.48, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.

SEC source: 0001562180-23-004067 · primarydocument.xml · nonDerivative · entry 5

Green Eric Mark · CIK 0001336007 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 135,074.0865

F2 · shares: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 9/14/2022. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. In total, 50,000 options were exercised with 44,000 shares sold and 6,000 shares held by the reporting person.

F6 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $364.425 to $365.295, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.

SEC source: 0001562180-23-004067 · primarydocument.xml · nonDerivative · entry 4

Green Eric Mark · CIK 0001336007 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 139,207.0865

F2 · shares: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 9/14/2022. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. In total, 50,000 options were exercised with 44,000 shares sold and 6,000 shares held by the reporting person.

F5 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $363.42 to $364.41, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.

SEC source: 0001562180-23-004067 · primarydocument.xml · nonDerivative · entry 3

Green Eric Mark · CIK 0001336007 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 151,855.0865

F2 · shares: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 9/14/2022. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. In total, 50,000 options were exercised with 44,000 shares sold and 6,000 shares held by the reporting person.

F4 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $362.42 to $363.41, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.

SEC source: 0001562180-23-004067 · primarydocument.xml · nonDerivative · entry 2

Green Eric Mark · CIK 0001336007 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 164,417.0865

F2 · shares: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 9/14/2022. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. In total, 50,000 options were exercised with 44,000 shares sold and 6,000 shares held by the reporting person.

F3 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $361.42 to $362.41, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.

SEC source: 0001562180-23-004067 · primarydocument.xml · nonDerivative · entry 1

Green Eric Mark · CIK 0001336007 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 178,574.0865

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The shares reported were acquired by the Reporting Person from exercising a portion of a stock option award expiring in 2025, pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was completed pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on 9/14/2022.

SEC source: 0001415889-23-007493 · form4-05052023_100514.xml · derivative · entry 3

Green Eric Mark · CIK 0001336007 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 554

Underlying: Common Stock · 554 shares

Expires 2033-05-04

F1 · derivative.exercise_date: The option will become exercisable, on a cumulative basis, as to 25% of the option shares (excluding any fractional portion less than one share), on the last day of each of the first, second and third three-month periods following its date of grant and as to the remaining shares on the last day of the fourth three-month period following its date of grant; provided, however, that if a Change in Control of the Company (as that term is defined in the Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan) will occur, then the option will become immediately exercisable in full.

SEC source: 0001415889-23-007493 · form4-05052023_100514.xml · derivative · entry 2

Green Eric Mark · CIK 0001336007 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,410

Underlying: Common Stock · 1,410 shares

Expires 2033-05-04

F1 · derivative.exercise_date: The option will become exercisable, on a cumulative basis, as to 25% of the option shares (excluding any fractional portion less than one share), on the last day of each of the first, second and third three-month periods following its date of grant and as to the remaining shares on the last day of the fourth three-month period following its date of grant; provided, however, that if a Change in Control of the Company (as that term is defined in the Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan) will occur, then the option will become immediately exercisable in full.

SEC source: 0001415889-23-006098 · form4-04042023_090430.xml · nonDerivative · entry 2

Green Eric Mark · CIK 0001336007 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 427.64